Chang C C, Sheikh V, Sereti I, French M A
Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, 3000, Australia.
Curr HIV/AIDS Rep. 2014 Sep;11(3):223-32. doi: 10.1007/s11904-014-0213-0.
An immune reconstitution disorder occurs in up to 40 % of severely immunodeficient HIV patients who commence antiretroviral therapy (ART), with an immune reconstitution inflammatory syndrome (IRIS) being encountered most commonly. Differences in the immunopathogenesis of an IRIS associated with different types of pathogen have become apparent but common features have also been defined. These include severe immunodeficiency prior to commencing ART associated with a high pathogen load and 'compensatory' immune responses, particularly innate immune responses, which inadequately control the pathogen and increase the risk of immunopathology as the immune system recovers on ART. Prevention of an IRIS may be achieved by optimising therapy for opportunistic infections before ART is commenced, delaying ART or using immunomodulatory therapy to prevent or suppress the immune response that causes the immunopathology. However, further clinical studies are required to examine these options in a systematic manner for the various types of IRIS.
高达40%开始抗逆转录病毒疗法(ART)的严重免疫缺陷HIV患者会出现免疫重建障碍,其中最常见的是免疫重建炎症综合征(IRIS)。与不同类型病原体相关的IRIS免疫发病机制的差异已很明显,但也确定了一些共同特征。这些特征包括开始ART之前的严重免疫缺陷,伴有高病原体载量和“代偿性”免疫反应,特别是先天免疫反应,这些反应无法充分控制病原体,并且随着免疫系统在ART治疗下恢复,会增加免疫病理的风险。在开始ART之前优化机会性感染的治疗、延迟ART或使用免疫调节疗法来预防或抑制引起免疫病理的免疫反应,可能实现对IRIS的预防。然而,需要进一步的临床研究以系统的方式检查针对各种类型IRIS的这些选择。